Fingolimod/Tofacitinib

芬戈莫德/托法替布

Report date: 2025/09/05 16:48:06

Base Information

Drug NameFingolimod/Tofacitinib
Drug Alias Name盐酸芬戈莫德/枸橼酸托法替布盐酸芬戈莫德/托西替尼盐酸芬戈莫德/托法尼布盐酸芬戈莫德/托法替尼盐酸芬戈利德/枸橼酸托法替布 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-phosphate receptor 4 modulatorsSphingosine 1-phosphate receptor 3 modulatorsSphingosine 1-phosphate receptor 2 modulators +[7] 
TargetsSphingosine 1-phosphate receptor 3Sphingosine 1-Phosphate Receptor 1Sphingosine 1-phosphate receptor 4 +[7] 
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsYes Fingolimod HydrochlorideTofacitinib Citrate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVyne Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVyne Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A